Basit öğe kaydını göster

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

dc.contributor.authorAKOVA, MURAT
dc.contributor.authorErdinc, Fatma Sebnem
dc.contributor.authorAKALIN, EMİN HALİS
dc.contributor.authorTABAK, Ömer Fehmi
dc.contributor.authorPULLUKÇU, HÜSNÜ
dc.contributor.authorBatum, Ozgur
dc.contributor.authorTURHAN, ÖZGE
dc.contributor.authorYildirmak, Mustafa Taner
dc.contributor.authorKÖKSAL, IFTAHAR
dc.contributor.authorDURUSU TANRIÖVER, MİNE
dc.contributor.authorDoganay, Hamdi Levent
dc.contributor.authorKose, Sukran
dc.contributor.authorGuner, Hatice Rahmet
dc.contributor.authorAzap, Alpay
dc.contributor.authorAKHAN, SILA
dc.contributor.authorTAŞOVA, YEŞİM
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorYILMAZ, GÜRDAL
dc.contributor.authorÇELEN, MUSTAFA KEMAL
dc.contributor.authorAltin, Sedat
dc.contributor.authorCelik, Ilhami
dc.contributor.authorBAYINDIR, YAŞAR
dc.contributor.authorKaraoglan, Ilkay
dc.contributor.authorYilmaz, Aydin
dc.contributor.authorÖZKUL, AYKUT
dc.contributor.authorGur, Hazal
dc.contributor.authorÜNAL, SERHAT
dc.contributor.authorYavuz, Serap Simsek
dc.date.accessioned2021-12-10T11:50:39Z
dc.date.available2021-12-10T11:50:39Z
dc.date.issued2021
dc.identifier.citationDURUSU TANRIÖVER M., Doganay H. L. , AKOVA M., Guner H. R. , Azap A., AKHAN S., Kose S., Erdinc F. S. , AKALIN E. H. , TABAK Ö. F. , et al., "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.", Lancet (London, England), cilt.398, sa.10296, ss.213-222, 2021
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_9803421a-f9e2-4607-b4ae-438defeb215f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172739
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(21)01429-x
dc.description.abstractBackground CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.
dc.language.isoeng
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleEfficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
dc.typeMakale
dc.relation.journalLancet (London, England)
dc.contributor.departmentHacettepe Üniversitesi , Tıp Fakültesi (Türkçe) , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume398
dc.identifier.issue10296
dc.identifier.startpage213
dc.identifier.endpage222
dc.contributor.firstauthorID2694734


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster